Lumos Diagnostics Holdings Ltd
ASX:LDX
Net Margin
Lumos Diagnostics Holdings Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
AU |
L
|
Lumos Diagnostics Holdings Ltd
ASX:LDX
|
53.9m AUD |
-34%
|
|
CH |
![]() |
Alcon AG
SIX:ALC
|
36B CHF |
11%
|
|
JP |
![]() |
Hoya Corp
TSE:7741
|
6.6T JPY |
23%
|
|
DK |
![]() |
Coloplast A/S
CSE:COLO B
|
139.3B DKK |
16%
|
|
US |
![]() |
Align Technology Inc
NASDAQ:ALGN
|
15B USD |
10%
|
|
CH |
![]() |
Ypsomed Holding AG
SIX:YPSN
|
5.9B CHF |
12%
|
|
UK |
![]() |
ConvaTec Group PLC
LSE:CTEC
|
4.9B GBP |
8%
|
|
CN |
![]() |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
44.9B CNY |
40%
|
|
US |
![]() |
Merit Medical Systems Inc
NASDAQ:MMSI
|
5B USD |
9%
|
|
CA |
![]() |
Bausch + Lomb Corp
NYSE:BLCO
|
5.1B USD |
-8%
|
|
US |
![]() |
Lantheus Holdings Inc
NASDAQ:LNTH
|
5B USD |
17%
|
Lumos Diagnostics Holdings Ltd
Glance View
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Lumos Diagnostics Holdings Ltd's most recent financial statements, the company has Net Margin of -34%.